Axolotl Graft Portfolio Clinical Validation

About Axolotl Biologix

Axolotl Biologix is a private, commercial-stage company developing and marketing a portfolio of human amnion-based allografts for wound healing and tissue repair. The company's core value proposition is its commitment to evidence-based medicine, with multiple peer-reviewed publications and an ongoing randomized controlled trial (RCT) supporting its products. With over 30,000 patients treated, products used in 44 states, and strategic partnerships for distribution, Axolotl is positioned in the growing regenerative biologics market, focusing on accessibility across acute and outpatient care sites.

Therapeutic Areas

Other Wound Healing / Tissue Repair Drugs